Literature DB >> 25601645

Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users.

Chih-Ken Chen1, Shih-Ku Lin2, Yi-Chih Chen1, Ming-Chy Huang3, Tzu-Ting Chen4, Shao Chun Ree1, Liang-Jen Wang5.   

Abstract

BACKGROUND: Prolonged exposure to methamphetamine (meth) has neurotoxic effects and impairs neurocognitive functions. This study aims to ascertain whether meth users who experience persistent psychosis suffer more severe cognitive impairment than those not experiencing persistent psychosis.
METHODS: This cross-sectional study includes 252 participants: 25 meth users without psychosis (METH-P), 50 with brief psychosis (METH+BP), and 56 with persistent psychosis (METH+PP), as well as 54 patients with schizophrenia and 67 healthy controls. The neurocognitive function and clinical psychopathology of each patient were evaluated with the Brief Assessment of Cognition in Schizophrenia (BACS) and the Brief Psychiatric Rating Scale (BPRS), respectively.
RESULTS: All cognitive domains evaluated with BACS (verbal memory, working memory, motor speed, verbal fluency, attention and processing speed, executive function, and composite scores) in METH+PP patients were similar to those in the schizophrenia patients and were worse than those in METH-P, METH+BP, and the healthy control subjects. Furthermore, cognitive functioning in meth users that did not experience persistent psychosis showed no statistically significant difference compared with the healthy control subjects. Among the meth users in this study, the negative symptom scores in the BPRS correlated to cognitive performance on the BACS, with the exception of motor speed.
CONCLUSIONS: Meth users display heterogeneity in their psychotic symptoms and cognitive profiles. Therefore, persistent psychotic symptoms may denote a risk for cognitive decline among meth users. Further longitudinal studies should be performed in the future to clarify the causal relationship between cognitive deficits and the development of persistent psychosis.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; Neuropsychological test; Psychosis; Psychostimulant; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 25601645     DOI: 10.1016/j.drugalcdep.2014.12.035

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  10 in total

1.  Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study.

Authors:  Tracy L Hellem; Young-Hoon Sung; Xian-Feng Shi; Marjorie A Pett; Gwen Latendresse; Jubel Morgan; Rebekah S Huber; Danielle Kuykendall; Kelly J Lundberg; Perry F Renshaw
Journal:  J Dual Diagn       Date:  2015

2.  Cognitive profile of ketamine-dependent patients compared with methamphetamine-dependent patients and healthy controls.

Authors:  Liang-Jen Wang; Chih-Ken Chen; Shih-Ku Lin; Yi-Chih Chen; Ke Xu; Ming-Chyi Huang
Journal:  Psychopharmacology (Berl)       Date:  2018-04-30       Impact factor: 4.530

3.  Outcome of treatment in patients with methamphetamine poisoning in an Iranian tertiary care referral center.

Authors:  Parva Paydar; Ali Mohammad Sabzghabaee; Hooman Paydar; Nastaran Eizadi-Mood; Ali Joumaa
Journal:  J Res Pharm Pract       Date:  2015 Jul-Sep

4.  Differential patterns of blood oxygenation in the prefrontal cortex between patients with methamphetamine-induced psychosis and schizophrenia.

Authors:  Kazuhiko Yamamuro; Manabu Makinodan; Sohei Kimoto; Naoko Kishimoto; Tsubasa Morimoto; Michihiro Toritsuka; Kiwamu Matsuoka; Yoshihiro Takebayashi; Tomoyo Takata; Masato Takahashi; Yoshinori Tanimura; Yosuke Nishihata; Yasuhiro Matsuda; Toyosaku Ota; Hiroki Yoshino; Junzo Iida; Toshifumi Kishimoto
Journal:  Sci Rep       Date:  2015-07-16       Impact factor: 4.379

5.  Clinical features, course and treatment of methamphetamine-induced psychosis in psychiatric inpatients.

Authors:  Homa Zarrabi; Mohammadrasoul Khalkhali; Azam Hamidi; Reza Ahmadi; Maryam Zavarmousavi
Journal:  BMC Psychiatry       Date:  2016-02-25       Impact factor: 3.630

6.  Cognitive Functioning in Schizophrenia, Methamphetamine-induced Psychotic Disorder, and Healthy People: A Comparative Study.

Authors:  Mohammadrasoul Khalkhali; Mahboobeh Golshahi; Tolou Hasandokht; Moosa Kafie; Roghaye Zare
Journal:  Adv Biomed Res       Date:  2018-08-31

7.  A Comparison Study of Working Memory Deficits between Patients with Methamphetamine-Associated Psychosis and Patients with Schizophrenia.

Authors:  Hong Gan; Zhenhua Song; Peiwei Xu; Hang Su; Yingying Pan; Min Zhao; Dengtang Liu
Journal:  Shanghai Arch Psychiatry       Date:  2018-06-25

8.  Emotion Recognition and Impulsive Choice in Relation to Methamphetamine Use and Psychosis Symptoms.

Authors:  Shalini Arunogiri; Antonio Verdejo-Garcia; Rebecca McKetin; Adam J Rubenis; Rebecca E Fitzpatrick; Dan I Lubman
Journal:  Front Psychiatry       Date:  2019-12-13       Impact factor: 4.157

Review 9.  A Comparison of Methamphetamine-Induced Psychosis and Schizophrenia: A Review of Positive, Negative, and Cognitive Symptomatology.

Authors:  Travis A Wearne; Jennifer L Cornish
Journal:  Front Psychiatry       Date:  2018-10-10       Impact factor: 4.157

10.  Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients.

Authors:  Gang Wang; Fan Ding; Marek Cezary Chawarski; Wei Hao; Xuebing Liu; Qijian Deng; Xuan Ouyang
Journal:  Front Psychiatry       Date:  2020-04-01       Impact factor: 4.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.